Nov 09, 2023 / 05:00PM GMT
Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
Good afternoon, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analyst here. It's my pleasure to have Vertex Pharmaceuticals with us here today.
On behalf of the company, we have Charlie Wagner, CFO; and David Altshuler, the Chief Scientific Officer. So thank you both for your time today.
Questions and Answers:
Colin Nigel Bristow - UBS Investment Bank, Research Division - AnalystMaybe we can just kick off with cystic fibrosis, obviously, a sort of major franchise for you guys, continue to show impressive quarter-on-quarter growth. But from an investor perspective, it feels that this is well understood. It's pretty well modeled. As you look at consensus estimates and you speak to investors, what do you think is underappreciated about this opportunity, if anything.
Charles F. Wagner - Vertex Pharmaceuticals Incorporated - Executive VP & CFO
Yes, Colin, thanks for the question. Maybe I'll start
Trustpilot
